Cassava Sciences Offers a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Insight Clinical Trials is now offering the the first phase 3 study to evaluate safety and efficacy of Simufilam. The trial will take place over 52 weeks and only 750 patients with Alzheimer’s disease will be accepted nationwide. The trial is open to those ages 50-87 years who suffer from mild cognitive impairment, dementia or Alzheimer's disease.
Cassava Sciences’ Phase 3 efficacy studies of Simufilam in Alzheimer’s disease are being conducted under Special Protocol Assessments (SPA) from the U.S. Food and Drug Administration (FDA).
“We believe existing drug solutions for Alzheimer’s have limitations, and new solutions are very much needed. Our Phase 3 studies are designed to evaluate the safety and efficacy of Simufilam in people with Alzheimer’s disease,” said Remi Barbier, President & CEO, Cassava Sciences.
Cassava Sciences is developing Simufilam in accordance with high ethical standards and sound scientific principles. Cassava Sciences is committed to transparency and sharing information related to its Phase 3 program – for clinical protocol details, including patient eligibility, please visit: https://ClinicalTrials.gov/ct2/show/NCT04994483.
Key Benefits of Volunteering in a Clinical Trial:
Taking a more active role in your healthcare
Getting regular expert medical care
Having additional talks with the study staff to discuss healthy lifestyle choices
Helping others by contributing to medical research
What will be required if I take part?
Initially, you will go through a screening process to ensure that you meet the criteria for being included in the study. If you do, your study doctor will explain exactly what is expected of a study participant so you can make an informed decision. Participation in the study will include:
A daily dose of the study medicine, prescribed by the study doctor
Attending regular study visits for study-related health checks and examinations
Undergoing an MRI or CT scan
Undergoing a PET scan or lumbar puncture test
Regular contact with the study nurse or the study doctor throughout the study.
To see if you may pre-qualify for the study, call Insight Clinical Trials at (216) 526-1843 or fill out this form.
About Simufilam
Simufilam (sim-uh-FILL-am) is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA) protein in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation. The underlying science for Simufilam is published in peer-reviewed journals, including Journal of Neuroscience, Neurobiology of Aging, Journal of Biological Chemistry, Neuroimmunology and Neuroinflammation and Journal of Prevention of Alzheimer’s Disease.
About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com.
Patients Receive:
All Services Free Of Charge
Keep Existing Treatment Team
Complete Confidentiality
Compensation Available
Transportation Available
NO insurance required
Receive all imaging and lab work
To see if you may pre-qualify for the study, call Insight Clinical Trials at (216) 526-1843 or fill out this form.